Diagnostic and therapeutic differences between immune checkpoint inhibitor‐induced and idiopathic bullous pemphigoid: a cross‐sectional study

Bullous pemphigoid (BP) is a serious, rare complication from immune checkpoint inhibitors (ICIs). While most dermatologic immune-related adverse events (irAEs) present early and are mild, ICI-induced BP (ICI-BP) manifests months into therapy and can prompt ICI discontinuation and severe immunosuppression. Following irAE management guidelines, providers rely on systemic corticosteroids - which, at high doses, may confer poorer oncologic outcomes for ICI patients. Our study aims to identify diagnostic and therapeutic differences between ICI-BP and idiopathic BP (iBP) to assist providers in prompt recognition and management of this skin toxicity.